abstract |
A novel pharmaceutical composition comprising the NK 3 receptor antagonists talnetant, povidone, erythritol and a surfactant, and a process for its preparation are disclosed. Disclosed is the use of erythritol as a soluble filler in the preparation of a stable pharmaceutical composition. |